Stock Details
PFE is Pfizer Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 50.60$. Average daily volumn in 3 months 24.51M. Market cap 293.51B



Stock symbol : PFE. Exchange : NYSE. Currency : USD
Lastest price : 52.31$. Total volume : 16.14M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Pfizer Inc. (PFE)
Last Price
52.31$
Change
-0.12
Volume
16.14M

Previous Close52.43
Open52.04
Day Range51.25-52.37
Bid51.92 x 1k
Ask51.90 x 4k
Volume16.14M
Average Volume24.51M
Market Cap293.51B
Beta0.71
52 Week Range38.93-61.71
Trailing P/E11.78
Foward P/E0.96
Dividend (Yield %)3.06%
Ex-Dividend Date2022-07-28



Financial Details


According to Pfizer Inc.'s financial reports the company's revenue in 2021 were 81.29B an increase( +97.56%) over the years 2020 revenue that were of 41.65B. In 2021 the company's total earnings were 21.98B while total earnings in 2020 were 9.16B( +133.33%).


Loading ...



Organization

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 trea... tment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Market Cap:
293.51B
Revenue:
81.29B
Total Assets:
181.48B
Total Cash:
1.94B


News about "Pfizer Inc."

pfizer-inc-nysepfe-shares-sold-by-eastern-bank-image

Pfizer Inc. (NYSE:PFE) Shares Sold by Eastern Bank

Source from : Defense World - 7 hours ago

Eastern Bank lowered its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 11.8% during the first quarter, according to the company in its most recent disclosure with the Securities and ...See details»


busey-wealth-management-reduces-position-in-pfizer-inc-nysepfe-image

Busey Wealth Management Reduces Position in Pfizer Inc. (NYSE:PFE)

Source from : Defense World - 7 hours ago

Busey Wealth Management decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.5% in the first quarter, Holdings Channel.com reports. The institutional investor owned 612,119 ...See details»


curevac-sues-biontech-over-mrna-and-covid-vaccines-pfizer-stock-isnt-spared-image

CureVac Sues BioNTech Over mRNA and Covid Vaccines. Pfizer Stock Isn’t Spared.

Source from : Barron's - 7 hours ago

CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.See details»


pfizers-updated-covid-19-vaccine-effective-against-omicron-could-boost-sales-image

Pfizer's Updated COVID-19 Vaccine Effective Against Omicron, Could Boost Sales

Source from : Investopedia - 5 days ago

Pfizer's new COVID-19 vaccine candidate could be used as a fourth booster dose to protect against the Omicron variant, helping to further boost sales.See details»


pfizer-signs-new-32-billion-covid-vaccine-deal-with-us-government-image

Pfizer signs new $3.2 billion COVID vaccine deal with U.S. government

Source from : Reuters - 5 days ago

Pfizer Inc and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later ...See details»


pfizer-asks-for-formal-us-approval-of-oral-covid-treatment-paxlovid-image

Pfizer asks for formal U.S. approval of oral COVID treatment Paxlovid

Source from : Reuters - 5 days ago

Pfizer Inc said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).See details»


How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence

Source from : Bozeman Daily Chronicle - 10 hours ago

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as covid-19 continues to infect ...See details»


pfizer-seeks-fdas-full-approval-for-paxlovid-covid-19-pill-image

Pfizer Seeks FDA’s Full Approval for Paxlovid Covid-19 Pill

Source from : Wall Street Journal - 5 days ago

Approval of Paxlovid, which has been available under an Food and Drug Administration authorization for use during the pandemic, would allow Pfizer to market and sell it commercially.See details»


pfizer-pfe-seeks-fda-nod-for-its-oral-antiviral-covid-pill-image

Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill

Source from : YAHOO!Finance - 4 days ago

Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.See details»


is-pfizer-inc-nysepfe-popular-amongst-institutions-image

Is Pfizer Inc. (NYSE:PFE) Popular Amongst Institutions?

Source from : YAHOO!Finance - 8 days ago

Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares ...See details»


Pfizer Inc. (PFE) Is A Good Investment At Current Valuations

Source from : stocksregister - 4 days ago

Pfizer Inc. (NYSE:PFE) at last check was buoying at $51.68 on Friday, July 01 with a fall of -1.43% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»


Pfizer And BioNTech Reach New Agreement With U.S. To Provide Addl Doses Of COVID-19 Vaccine

Source from : Nasdaq - 5 days ago

Pfizer Inc. (PFE) and BioNTech SE (BNTX) have reached a new supply agreement with the U.S. government to provide additional doses of COVID-19 Vaccine, the companies said in a statement. Under the ...See details»


pfizer-inc-nysepfe-shares-sold-by-pennsylvania-capital-management-inc-adv-image

Pfizer Inc. (NYSE:PFE) Shares Sold by Pennsylvania Capital Management Inc. ADV

Source from : ETF Daily News - 7 days ago

Pennsylvania Capital Management Inc. ADV lessened its stake in Pfizer Inc. (NYSE:PFE – Get Rating) by 67.8% during the 1st quarter, according to its most recent 13F filing with the Securities & ...See details»


is-trending-stock-pfizer-inc-pfe-a-buy-now-image

Is Trending Stock Pfizer Inc. (PFE) a Buy Now?

Source from : Yahoo News Singapore - 4 days ago

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.See details»